Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 8;29(10):7537-7551.
doi: 10.3390/curroncol29100593.

Hepatocellular Carcinoma, Alpha Fetoprotein, and Liver Allocation for Transplantation: Past, Present and Future

Affiliations
Review

Hepatocellular Carcinoma, Alpha Fetoprotein, and Liver Allocation for Transplantation: Past, Present and Future

Brianna Ruch et al. Curr Oncol. .

Abstract

Hepatocellular carcinoma (HCC) is one of the leading indications for liver transplantation and has been the treatment of choice due to the oncologic benefit for patients with advanced chronic liver disease (AdvCLD) and small tumors for the last 25 years. For HCC patients undergoing liver transplantation, alpha fetoprotein (AFP) has increasingly been applied as an independent predictor for overall survival, disease free recurrence, and waitlist drop out. In addition to static AFP, newer studies evaluating the AFP dynamic response to downstaging therapy show enhanced prognostication compared to static AFP alone. While AFP has been utilized to select HCC patients for transplant, despite years of allocation policy changes, the US allocation system continues to take a uniform approach to HCC patients, without discriminating between those with favorable or unfavorable tumor biology. We aim to review the history of liver allocation for HCC in the US, the utility of AFP in liver transplantation, the implications of weaving AFP as a biomarker into policy. Based on this review, we encourage the US transplant community to revisit its HCC organ allocation model, to incorporate more precise oncologic principles for patient selection, and to adopt AFP dynamics to better stratify waitlist dropout risk.

Keywords: alpha fetoprotein; hepatocellular carcinoma; liver allocation; liver transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
AFP structure model. Copyright© 2022 Mingyue Zhu et al. is licensed under CC BY 3.0 [11].
Figure 2
Figure 2
US Liver Allocation Policy and Changes.
Figure 3
Figure 3
HCC Prediction Models over time. As time has progressed, a greater focus on AFP inclusion is noted in developing prediction models for recurrence-free survival in the setting of liver transplantation.

Similar articles

Cited by

References

    1. Chidambaranathan-Reghupaty S., Fisher P.B., Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv. Cancer Res. 2021;149:1–61. doi: 10.1016/bs.acr.2020.10.001. - DOI - PMC - PubMed
    1. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576. doi: 10.1053/j.gastro.2007.04.061. - DOI - PubMed
    1. Ding J., Wen Z. Survival improvement and prognosis for hepatocellular carcinoma: Analysis of the SEER database. BMC Cancer. 2021;21:1157. doi: 10.1186/s12885-021-08904-3. - DOI - PMC - PubMed
    1. Trevisani F., Garuti F., Neri A. Alpha-fetoprotein for Diagnosis, Prognosis, and Transplant Selection. Semin. Liver Dis. 2019;39:163–177. doi: 10.1055/s-0039-1677768. - DOI - PubMed
    1. OPTN 2020 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 2009–2020. [(accessed on 8 January 2022)]. Available online: https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.16975. - DOI

Grants and funding

This research received no external funding.
  NODES
COMMUNITY 1
INTERN 2
Note 1
twitter 2